Lexeo Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Lexeo Therapeutics has a total shareholder equity of $164.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $192.0M and $27.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$174.98m |
| Equity | US$164.95m |
| Total liabilities | US$27.06m |
| Total assets | US$192.01m |
Recent financial health updates
We're Hopeful That Lexeo Therapeutics (NASDAQ:LXEO) Will Use Its Cash Wisely
Oct 11
We're Hopeful That Lexeo Therapeutics (NASDAQ:LXEO) Will Use Its Cash Wisely
Jun 18Recent updates
We're Hopeful That Lexeo Therapeutics (NASDAQ:LXEO) Will Use Its Cash Wisely
Oct 11Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further
Jul 16We're Hopeful That Lexeo Therapeutics (NASDAQ:LXEO) Will Use Its Cash Wisely
Jun 18Lexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay Off
Apr 09Lexeo Therapeutics: Only Smallcap Gene Therapy For Alzheimer's
Jan 29Financial Position Analysis
Short Term Liabilities: LXEO's short term assets ($177.1M) exceed its short term liabilities ($18.9M).
Long Term Liabilities: LXEO's short term assets ($177.1M) exceed its long term liabilities ($8.2M).
Debt to Equity History and Analysis
Debt Level: LXEO is debt free.
Reducing Debt: LXEO had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LXEO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: LXEO has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 28.7% each year.